These findings could have therapeutic implications since combination treatment of tumor xenografts of tamoxifen resistant breast cancer cells, BT474, with a MYC inhibitor (10058-F4) and HER2 inhibitor (Trastuzumab) significantly reduced tumor growth in immunodeficient NSG mice (Figure 1). Here, ERBB2 is linked to breast cancer.